New publication - team 3

New publication - Team 3

Publication date: 18 April 2022

Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer

OncoImmunology Volume 11, 2022 - Issue 1

Authors: Kathleen Ducoin, Romain Oger, Linda Bilonda Mutala, Cécile Deleine, Nicolas Jouand, Juliette Desfrançois, Juliette Podevin, Emilie Duchalais, Jonathan Cruard, Houssem Benlalam, Nathalie Labarrière, Céline Bossard, Anne Jarry and Nadine Gervois-Segain

Link to the publication :: https: //www.tandfonline.com/doi/epub/10.1080/2162402X.2022.2046931?needAccess=true

Come and discover the projects of Team 3

"2 prizes for Incit at the Go Immuno congress - December 11 & 12, 2023".

Headlines, Oncology, Events, Immunotherapy, Inflammation

INCIT in the spotlight at the "Go Immuno" conference organized by Labex IGO in December. In...

European funding for immunotherapy of inflammatory bowel diseases

Headlines, Inflammation, New Financing

HORIZON Europe Framework Program : coordinated by F. ALTARE INCIT joins the RAISE network...

"Cross-talks between Death Receptor signalling and ER stress response in cancer".

Oncology, Immunotherapy, Seminar

Seminar Speaker: Elodie Lafont (U1242 Inserm, Centre...

Previous entries

"2 prizes for Incit at the Go Immuno congress - December 11 & 12, 2023".

Dec 13, 2023 | Oncology, Event, Immunotherapy, Inflammation, Headlines

INCIT was honored at the "Go Immuno" conference organized by Labex IGO in December. Margaux Verdon (team 1) was awarded the prize for best poster, while Gwenann Cadiou (team 3) won the prize for best oral communication!

European funding for immunotherapy of inflammatory bowel diseases

Dec 13, 2022 | Headlines, Inflammation, New Financing

The INCIT unit is pleased to announce that it has been awarded an ambitious European program on immunotherapy, bringing together 7 partners (including 2 biotechs) in 4 European countries. This program is coordinated by Frédéric ALTARE, Director of the UMR 1302, INCIT in Nantes. Project title: immunotherapy of inflammatory bowel diseases

"Cross-talks between Death Receptor signalling and ER stress response in cancer".

Nov 23, 2023 | Oncology, Immunotherapy, Seminar

Dr Elodie Lafont (U1242 Inserm, Centre Eugène Marquis, Rennes), guest of Team 2, will give a seminar entitled: Cross-talks between Death Receptor signalling and ER stress response in cancer , on November 27 at 14.00 - Rooms 1, 2, 3 - IRS2, Nantes

"Reactivation of the STING pathway to improve the efficacy of immunotherapies (anti-PD(L)1) in heterotypic spheroid models of urothelial carcinoma."

June 6, 2023 | Oncology, Immunotherapy, Seminar

Dr Céline Gongora (Institut de cancérologie de Montpellier (IRCM), guest of Team 3, will give a seminar entitled: Reactivation of the STING pathway to improve the efficacy of immunotherapies (anti-PD-(L)1) in urothelial carcinoma models , June 21 at 11.00 - Rooms 1, 2, 3 - IRS2, Nantes

Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer

"2 prizes for Incit at the Go Immuno congress - December 11 & 12, 2023".

European funding for immunotherapy of inflammatory bowel diseases

"Cross-talks between Death Receptor signalling and ER stress response in cancer".

"2 prizes for Incit at the Go Immuno congress - December 11 & 12, 2023".

European funding for immunotherapy of inflammatory bowel diseases

"Cross-talks between Death Receptor signalling and ER stress response in cancer".

"Reactivation of the STING pathway to improve the efficacy of immunotherapies (anti-PD(L)1) in heterotypic spheroid models of urothelial carcinoma."

Incit Recruits

Useful links

Home

About us

Recruitment

News

Contact

FAQ

The teams

Team 1

Team 2

Team 3

Team 4

Legal

Legal information

Intranet

Log in

News :

Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer

Read also:

Read more articles